Targeting IL-4 for the Treatment of Atopic Dermatitis

• Published in: ImmunoTargets and therapy Vol. 9; pp. 151 - 156
• Main Authors: Chiricozzi, Andrea, Maurelli, Martina, Peris, Ketty, Girolomoni, Giampiero
• Format: Journal Article
• Language: English
• Published: Macclesfield Dove Medical Press Limited 01.01.2020; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Advertising executives; Atopic dermatitis; B cells; Cytokines; Dendritic cells; Dermatitis; Dupilumab; Eczema; Gene expression; Granulocytes; il-4; il-4 inhibitor; Immune response; Immunotherapy; Inflammation; Interleukin 13; Interleukin 4; Interleukins; Kinases; Lymphocytes; Monoclonal antibodies; Neurons; pascolizumab; Pathogenesis; pitrakinra; Review; Skin; Skin diseases
• ISSN: 2253-1556; 2253-1556
• DOI: 10.2147/ITT.S260370

Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4. Keywords: atopic dermatitis, IL-4, IL-4 inhibitor, dupilumab, pascolizumab, pitrakinra